Richard Barker elected to Celgene’s board of directors
pharmafile | January 24, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | ABPI, Celgene, Richard Barker
Celgene, the biopharma firm specialising in cancer and inflammatory diseases, has elected Richard Barker to its board of directors.
Dr Barker served as director general of the Association of the British Pharmaceutical Industry (ABPI) until last year, and as a board member for the European and international pharma industry federations.
He was formerly chief executive of Chiron Diagnostics, general manager of IBM’s worldwide healthcare solutions division and leader of McKinsey & Company’s European healthcare practice.
Dr Barker holds a D.Phil. in biophysics and a BA in chemistry, both from Oxford University.
He was also named as a senior advisor at Aegate last week, an authentication and traceability service for the pharma industry.
Related Content

NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

The November 2020 issue of Pharmafocus is available to read free online now!
The latest monthly edition of Pharmafocus is available to read for free online now!

UK life sciences industry does not want no-deal Brexit, says ABPI Chief
Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a …






